Thesis defense : “ Consequences of APP soluble forms overexpression in memory processes and its therapeutical application to Alzheimer’s disease.”
- Details
- Created on Thursday, 15 September 2016 08:50
Wednesday September the 21st, World Alzheimer's Day, will be held at CEA of Fontenay aux roses a thesis defense by Romain Fol on this topic. The discussion will precisely focus on the “ Consequences of APP soluble forms overexpression in memory processes and its therapeutical application to Alzheimer’s disease.”
THE SILENT STAGE OF ALZHEIMER’S DISEASE
- Details
- Created on Monday, 08 August 2016 06:46
http://icm-institute.org/en/actualite/the-silent-stage-of-alzheimers-disease/
A major international conceptual diagnostic criteria and conceptual breakthrough program has been successfully launched and published, led by the UPMC and ICM researchers Professor Bruno Dubois and Professor Harald Hampel (AXA – UPMC Chair) who coordinated a distinguished group of major international key opinion leaders, based on the dynamic conceptual evolution of the paradigm of preclinical Alzheimer’s disease (AD), in the March Issue of the leading international Alzheimer Journal Alzheimer’s & Dementia, The Journal of the Alzheimer’s Association.
Multiple Sclerosis: an essay raised hopes for aggressive forms
- Details
- Created on Thursday, 23 June 2016 14:00
Treatment successfully interrupted the occurrence of relapses in patients with an aggressive form of multiple sclerosis and to prevent the emergence of new brain lesions on MRI.
Stimulate the generation of myelin, a therapy for the CHARGE Syndrome?
- Details
- Created on Friday, 03 June 2016 09:55
CHARGE syndrome is a rare genetic disease (1/10 000 births) caused by mutation of a copy of CHD7 gene resulting in many defects. This syndrome is particularly recognized as the major cause of deafness and congenital blindness. In affected children, neurological disorders increase with age. The team of Dr. Parras to the ICM has shown that this anomaly would be linked to a deficient myelination. Their findings indicate that CHD7 gene is essential for the maturation of oligodendrocytes and myelin formation. This new potential therapeutic target could help develop new treatments for people suffering from diseases due to defects in myelination.
